Role of melatonin, melatonin receptors and STAT3 in the cardioprotective effect of chronic and moderate consumption of red wine

Biochemical and Biophysical Research Communications

Volumn 465, Issue 4, 2015, Pages 719-724

  Lamont, Kim ^a   Nduhirabandi, Frederic ^a   Adam, Tasneem ^a   Thomas, D Paul ^a   Opie, Lionel H ^a   Lecour, Sandrine ^a  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Cardioprotection; Ischemia reperfusion; Melatonin; Red wine; SAFE pathway

Indexed keywords

LUZINDOLE; MELATONIN; MELATONIN RECEPTOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PRAZOSIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; CARDIOTONIC AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; STAT3 PROTEIN, MOUSE; TRYPTAMINE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR 2; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EX VIVO STUDY; EXPERIMENTAL MYOCARDIAL ISCHEMIA; FLUID INTAKE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PERFUSION; HEART PROTECTION; IN VIVO STUDY; LONG TERM CARE; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RED WINE; REPERFUSION INJURY; TREATMENT DURATION; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DEFICIENCY; DIET THERAPY; GENETICS; HEART INFARCTION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; WINE; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; MALE; MELATONIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; PRAZOSIN; RATS; RATS, WISTAR; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTORS, MELATONIN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STAT3 TRANSCRIPTION FACTOR; TRYPTAMINES; TYRPHOSTINS; WINE;

EID: 84941317470     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.08.064     Document Type: Article

References (36)

1. L.H. Opie, and S. Lecour The red wine hypothesis: from concepts to protective signalling molecules Eur. Heart J. 28 2007 1683 1693
2. G. Chiva-Blanch, M. Urpi-Sarda, E. Ros, and et al. Dealcoholized red wine decreases systolic and diastolic blood pressure and increases plasma nitric oxide: short communication Circ. Res. 111 2012 1065 1068
3. K. Lamont, D. Blackhurst, Z. Albertyn, and et al. Lowering the alcohol content of red wine does not alter its cardioprotective properties S. Afr. Med. J. 102 2012 565 567
4. R. Semba, L. Ferrucci, B. Bartali, and et al. Resveratrol levels and all-causes mortality in older community-dwelling adults JAMA Intern. Med. 174 2014 1077 1084
5. A. Galano, D.X. Tan, and R.J. Reiter Melatonin as a natural ally against oxidative stress: a physicochemical examination J. Pineal Res. 51 2011 1 16
6. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and P. Avanzas The role of melatonin in acute myocardial infarction Front. Biosci. (Landmark Ed.) 17 2012 2433 2441
7. A. Lochner, B. Huisamen, and F. Nduhirabandi Cardioprotective effect of melatonin against ischaemia/reperfusion damage Front. Biosci. (Elite Ed.) 5 2013 305 315
8. D.X. Tan, L.C. Manchester, R.J. Reiter, and et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin J. Pineal Res. 25 1998 184 191
9. S. Vitalini, C. Gardana, P. Simonetti, and et al. Melatonin, melatonin isomers and stilbenes in Italian traditional grape products and their antiradical capacity J. Pineal Res. 54 2013 322 333
10. K.T. Lamont, S. Somers, L. Lacerda, and et al. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection J. Pineal Res. 50 2011 374 380
11. S. Lecour Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J. Mol. Cell Cardiol. 47 2009 32 40
12. L. Lacerda, S. Somers, L.H. Opie, and et al. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway Cardiovasc. Res. 84 2009 201 208
13. A. Ecarnot-Laubriet, M. Assem, F. Poirson-Bichat, and et al. Stage-dependent activation of cell cycle and apoptosis mechanisms in the right ventricle by pressure overload Biochim. Biophys. Acta 1586 2002 233 242
14. S.Y. Lim, S.M. Davidson, M.M. Mocanu, and et al. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore Cardiovasc. Drugs Ther. 21 2007 467 469
15. S. Lecour, N. Suleman, G.A. Deuchar, and et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase) Circulation 112 2005 3911 3918
16. S. Renaud, and M. de Lorgeril Wine, alcohol, platelets, and the French paradox for coronary heart disease Lancet 339 1992 1523 1526
17. R. Reiter, C. Swingen, L. Moore, and et al. Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction Circ. Res. 110 2012 105 110
18. I.B. Hickie, and N.L. Rogers Novel melatonin-based therapies: potential advances in the treatment of major depression Lancet 378 2011 621 631
19. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, E. Arroyo-Ucar, and et al. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction J. Pineal Res. 53 2012 319 323
20. A. Lochner, S. Genade, A. Davids, and et al. Short- and long-term effects of melatonin on myocardial post-ischemic recovery J. Pineal Res. 40 2006 56 63
21. G. Maarman, D. Blackhurst, F. Thienemann, and et al. Melatonin as a preventive and curative therapy against pulmonary hypertension J. Pineal Res. 2015 10.1111/jpi.12263
22. M. Iriti, E.M. Varoni, and S. Vitalini Melatonin in traditional Mediterranean diets J. Pineal Res. 49 2010 101 105
23. C.J. McMullan, E.S. Schernhammer, E.B. Rimm, and et al. Melatonin secretion and the incidence of type 2 diabetes JAMA 309 2013 1388 1396
24. Y.M. Wang, B.Z. Jin, F. Ai, and et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials Cancer Chemother. Pharmacol. 69 2012 1213 1220
25. S. Genade, A. Genis, K. Ytrehus, and et al. Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions J. Pineal Res. 45 2008 449 458
26. D.X. Tan, L.C. Manchester, M.P. Terron, and et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance J. Pineal Res. 43 2007 317 320
27. G. Galli-Carminati, N. Deriaz, and G. Bertschy Melatonin in treatment of chronic sleep disorders in adults with autism: a retrospective study Swiss Med. Wkly. 139 2009 293 296
28. M.E. Shaker, M.E. Houssen, E.M. Abo-Hashem, and et al. Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress J. Physiol. Biochem. 65 2009 225 233
29. D.X. Tan, R.J. Reiter, L.C. Manchester, and et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger Curr. Top. Med. Chem. 2 2002 181 197
30. C. Lagneux, M. Joyeux, P. Demenge, and et al. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart Life Sci. 66 2000 503 509
31. F. Ortiz, J.A. Garcia, D. Acuna-Castroviejo, and et al. The beneficial effects of melatonin against heart mitochondrial impairment during sepsis: inhibition of iNOS and preservation of nNOS J. Pineal Res. 56 2014 71 81
32. G. Petrosillo, G. Colantuono, N. Moro, and et al. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening Am. J. Physiol. Heart Circ. Physiol. 297 2009 H1487 H1493
33. M.A. Frias, S. Pedretti, D. Hacking, and et al. HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity Atherosclerosis 228 2013 110 116
34. K. Boengler, D. Hilfiker-Kleiner, G. Heusch, and et al. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion Basic Res. Cardiol. 105 2010 771 785
35. K. Boengler, E. Ungefug, G. Heusch, and et al. The STAT3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation Curr. Pharm. Des. 19 2013 6890 6895
36. G. Heusch, K. Boengler, and R. Schulz Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection Basic Res. Cardiol. 105 2010 151 154